Overall Perfomance for "Stock Sumo"
The following three charts can be used by potential investors to gauge the performance of "Stock Sumo":
240 out of 446 campaigns closed down on first day
167 out of 446 campaigns closed up on first day
39 out of 446 campaigns had no net effect
MDGS Promotional Newsletter
The following is a newsletter released by "Stock Sumo" promoting Medigus Ltd.
More options updates are on the menu for this morning, with a recap of yesterday's winners, as well as an update on one of our current running ideas.
From , we have the AMBA Weekly $112-115 Calls and the PLAN 0917 $65-75 Calls, as well as some new highs in the SLQT 0917 $7.50-10 Calls which we signaled .
AMBA Weekly $112-115 Calls
$112 7.30-19.96 173%
$113 7.60-19.00 150%
$115 3.00-17.60 487%
PLAN 0917 $65-75 Calls
$65 3.01-4.66 55%
$70 .92-1.85 101%
$75 .25-.50 100%
SLQT 0917 $7.50-10 Calls
$7.50 1.80-3.47 93%
$10 .40-1.25 212%
Fresh Options Ideas
CHPT Weekly $24-25 Calls
NTNX Weekly $37.50-40 Calls
SIG Weekly $80-90 Calls
CHWY Weekly $83-79 Puts
Medigus Ltd. MDGS - News Alert
Another fresh PR from MDGS this morning, alluding to a new patent filing pertaining to Polyrizon's cutting edge infection-resisting hydrogel technology. We've been tracking developments in MDGS' interests, and Polyrizon has been one of the most active.
OMER, Israel, Sept. 02, 2021 GLOBE NEWSWIRE -- Medigus Ltd. Nasdaq MDGS, a technology company engaged in advanced medical solutions, innovative internet technologies and electric vehicle and charging solutions, today announced that Polyrizon Ltd., a privately held company which Medigus owns 35.86% of its share capital, has submitted an additional patent application to the United States Patent and Trademark Office for its innovative technology.
The invention generally pertains to the field of hydrogels that are capable to capture and contain biological assaults intrusion through the upper airways and eye cavities. Furthermore, the invention details a novel modality for a delivery system for drugs through the nasal mucosa that could get more drug into the body, and resides longer in the nasal cavity.
Recent pre-clinical data by Polyrizon, showed that its product candidate has the potential to reduce the risk of an infection with human coronavirus and may also prevent COVID-19 as well as Influenza Virus H1N1 and may potentially also treat additional Cold viruses.
Metal Arts Co. Inc. MTRT - Recap
Lastly, we placed MTRT on watch in yesterday morning's premarket report, and got instant results in the form of an enormous single-session push from this OTC play.
The stock traded up from a low of .5778 on the day, and reach a high of 5.05, for a whopping intraday move of 774% which came in on more than 18X the 30-day average volume.
PSTV, IPHA, SPRT, CHPT, TLSA, GSM, CCAJ, TLSS, TPTW, APTY, RHCO, HBRM
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. is to be read and fully agreed to before using our site, or joining our email list. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions, however any that may occur will be corrected as needed. BHS and its affiliates are not registered or licensed investment advisers, nor broker dealers. BHS cautions that the investments in companies profiled are commonly considered to be extremely high risk and use of any information provided is at the investor's sole risk.
082321 Owners of this website received $25000USD from a Third-Party for a One Month Market Awareness Campaign on MDGS.
Copyright 2021 StockServant.com,